HAP Trading’s Rigel Pharmaceuticals RIGL Stock Holding History

HAP Trading’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,610	Closed	-$19K	–	2636
2021 Q1	$19K	Buy	+1,610	New	+$63.8K	﹤0.01%	1482

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HAP Trading's RIGL Position: Q1 2022 in Review

HAP Trading sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 9,996 shares — an estimated $271K sold.

HAP Trading first reported a position in RIGL in Q3 2016 and held it in 8 quarters. The position peaked at $1.13M in Q3 2016. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

HAP Trading reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
HAP Trading sold 9,996 Rigel Pharmaceuticals shares in Q1 2022, an estimated $271K.
HAP Trading first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 8 quarters.
HAP Trading's Rigel Pharmaceuticals position peaked at $1.13M in Q3 2016.
163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on HAP Trading's 13F filing for Q1 2022, filed 12 May 2022.